Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients

AIDS

Volumn 17, Issue 16, 2003, Pages 2337-2343

  Papasavvas, Emmanouil ^a   Grant, Robert M ^c   Sun, Junwei ^a   Mackiewicz, Agnieska ^a   Pistilli, Maxwell ^a   Gallo, Cecile ^b   Kostman, Jay R ^b   Mounzer, Karam ^b   Shull, Jane ^b   Montaner, Luis J ^a  

^a WISTAR INSTITUTE   (United States)

^b Philadelphia Fld Initiating Grp H   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic infection; Drug resistance; HIV 1; Mutations; Quasispecies; Treatment interruption; Wild type virus

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MUTATIONAL ANALYSIS; PATIENT MONITORING; PERSISTENT INFECTION; PRIORITY JOURNAL; REBOUND; THERAPY RESISTANCE; VIRUS GENE; VIRUS INHIBITION; VIRUS MUTATION;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION;

EID: 9144262301     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200311070-00008     Document Type: Article

References (21)

1. Larder B. Mechanisms of HIV-1 drug resistance. AIDS 2001, 15:S27-34.
2. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001, 344:472-480.
3. Neumann AU, Tubiana R, Calvez V, Robert C, Li TS, Agut H, et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS 1999, 13:677-683.
4. Garcia F, Plana M, Vidal C, Cruceta A, O'Brien WA, Pantaleo G, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999, 13:F79-F86.
5. Ruiz L, Martinez-Picado J, Romeu J, Paredes R, Zayat MK, Marfil S, et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 2000, 14:397-403.
6. Ruiz L, Carcelain G, Martinez-Picado J, Frost S, Marfil S, Paredes R, et al. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 2001, 15:F19-F27.
7. Ortiz GM, Nixon DF, Trkola A, Binley J, Jin X, Bonhoeffer S, et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest 1999, 104:R13-R18.
8. Davey RT, Jr, Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999, 96:15109-15114.
9. Frost SD, Martinez-Picado J, Ruiz L, Clotet B, Brown AJ. Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection. J Virol 2002, 76:968-979.
10. Dorman KS, Kaplan AH, Lange K, Sinsheimer JS. Mutation takes no vacation: can structured treatment interruptions increase the risk of drug-resistant HIV-1? J Acquir Immune Defic Syndr 2000, 25:398-402.
11. Richman D. The challenge of immune control of immunodeficiency virus. J Clin Invest 1999, 104:677-678.
12. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000, 283:381-390.
13. Garcia F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, Vidal C, et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001, 15:F29-F40.
14. Papasavvas E, Ortiz GM, Gross R, Sun J, Moore EC, Heymann JJ, et al. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis 2000, 182:766-775.
15. Carcelain G, Tubiana R, Samri A, Calvez V, Delaugerre C, Agut H, et al. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J Virol 2001, 75:234-241.
16. Martinez-Picado J, Morales-Lopetegi K, Wrin T, Prado JG, Frost SD, Petropoulos CJ, et al. Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS 2002, 16:895-899.
17. Montaner LJ, Doyle AG, Collin M, Herbein G, Illei P, James W, et al. Interleukin 13 inhibits human immunodeficiency virus type 1 production in primary blood-derived human macrophages in vitro. J Exp Med 1993, 178:743-747.
18. D'Aquila R, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter L, et al. Update on drug resistance mutations in HIV-1. HIV Med 2001, 9:31-33.
19. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002, 288:181-188.
20. Grant RM, Kuritzkes DR, Johnson V, Mellors JW, Sullivan JL, Swanstrom R, et al. Accuracy of the trugene HIV-1 genotyping kit. J Clin Microbiol 2003, 41:1586-1593.
21. Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picado J, D'Aquila R, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000, 14:2857-2867.